omniture
logo
Search
德琪（浙江）医药科技有限公司 Deqi (zhejiang) Pharmaceutical Technology Co. LTD
Media Room

Photo News

rss
Antengene Appoints Amily Zhang as its Chief Medical Officer

Antengene Appoints Amily Zhang as its Chief Medical Officer

2022-12-08 08:30 3376
Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

Antengene Unveils Its First Australian Office to Continue Expanding Global Presence

2022-09-14 08:30 3980
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting

2022-04-11 08:30 2577
Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

Treating Patients Beyond Borders - Antengene Successfully Hosted Its First R&D Day

2021-11-19 13:00 3394
Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

Antengene and Its Partners Publish Preclinical Data Demonstrating the Encouraging Activity of Selinexor in the Prevention and Treatment of SARS-CoV-2 Infections

2021-07-26 08:44 2761
Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

Antengene Appoints Kathryn Gregory as Vice President and Head of Corporate Business Development

2021-05-25 08:00 3362
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

2021-05-06 11:28 3550
Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

Antengene Announces XPO1 Inhibitor Selinexor Prescribed for the First Time in the Pilot Zone of Hainan Province and Authorized to be Expanded Beyond the Pilot Zone for Outpatient Treatment

2021-04-29 08:34 3245
Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

Antengene Presented Preclinical Data Demonstrating Potent Synergistic Effect of the Combination of ATG-010 (Selinexor) and ATG-008 (Onatasertib) for the Treatment of Triple-Hit DLBCL

2021-04-13 08:00 3269
Antengene Appoints Kevin Lynch as Chief Medical Officer

Antengene Appoints Kevin Lynch as Chief Medical Officer

2021-03-25 23:26 3526
Antengene Appoints Bo Shan as Chief Scientific Officer

Antengene Appoints Bo Shan as Chief Scientific Officer

2021-03-25 22:36 4015
Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

Antengene to Present Preclinical Data Demonstrating the Synergistic Effect of the Combination of XPO1 and mTORC1/2 Inhibition for the Treatment of Triple-Hit DLBCL at AACR Annual Meeting 2021

2021-03-22 08:00 2908
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea

2021-03-15 08:00 3652
Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference

Antengene to Present at the 39th Annual J.P. Morgan Healthcare Conference

2021-01-11 07:26 1741
Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

Antengene Announces Collaboration with WuXi Biologics to Advance the Development of Innovative Oncology Medicines

2020-10-15 08:59 2766
Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

Antengene's New Drug Discovery Center Established in Zhangjiang, Shanghai: Dedicated to the Research and Development of Innovative Therapies for Cancer

2020-10-12 20:00 4995
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

2020-07-20 08:00 9297
Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

Antengene Appoints Former Celgene ANZ Medical Leader Dirk Hoenemann as Head of Medical Affairs in Asia Pacific Region & Early Clinical Development

2020-07-13 06:00 4629
­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

­Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

2020-07-02 08:16 1557
Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

2020-06-08 20:00 2241
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions

2020-04-13 20:00 3348
12